Drug news
Ceptaris Therapeutics receives Complete Response Letter from FDA for mechlorethamine hydrochloride treatment for Mycosis Fungoides
Ceptaris Therapeutics (formerly Yaupon Therapeutics) has received a Complete Response Letter (CRL) from the FDA for mechlorethamine hydrochloride gel as a treatment for early-stage Mycosis Fungoides, the most common type of cutaneous T-Cell lymphoma a rare form of non-Hodgkin's lymphoma. Mechlorethamine hydrochloride is a water-soluble, greaseless topical gel, which could lead to better compliance for patients with Mycosis Fungoides.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.